Share This Post

Featured / Main Slider / Technology

FDA approves AI-triage telehealth radiological review

FDA approves AI-triage telehealth radiological review

Nines has announced the NinesAI medical device making artificial intelligence is available to the telehealth industry.

NinesAI is FDA-cleared and supports the automated radiological review of CT Head images for the possible presence of two time-critical, life-threatening indications – intracranial haemorrhage and mass effect – to aid radiologists in triaging cases. NinesAI will be​ deployed to radiologists in Nines’ teleradiology practice and will also be available to Nines’ customers for in-house use at no added cost. 

Radiologists suffer from high rates of burnout, according to MedScape’s Radiologist Lifestyle 2020 report,​ due to ever-increasing workload and suboptimal working conditions. Nines aims to relieve those burdens via more efficient workflows that positively impact patient care. Its team has developed Nines Navigator worklist and the Nines Reading Assistant, which are administrative, non-medical device programs to improve radiologist focus. ​NinesAI assists radiologists by alerting them to the possible presence of​ intracranial haemorrhage and mass effect on head CT scans, life-threatening conditions that can be prioritised for review and consultation with hospital physicians treating patients.  

Nines co-founder and CEO, David Stavens, said: “At Nines, we believe the application of advanced technology can address complex and pressing challenges in healthcare, and in particular for radiology, solve for a higher rate of burnout among radiologists. With clearance from FDA, we’re proud to offer transformative AI innovation supporting the prioritisation and triage of emergent conditions to complement radiologists’ work and ultimately improve the quality of patient care. We’re excited to partner with customers who seek cutting edge tools to deal with the conditions that matter most for patients.”

Med-Tech Innovation

Share This Post

Leave a Reply